Reliable, Comprehensive, and Rapid Sexual Health Assessment

ABSTRACT

A system and method for detecting status of a health condition in a single-step process includes: a signal output device including a) a loading zone; b) a reaction zone fluidly coupled to the loading zone and including one or more reaction substances conjugated to labels, configured to enable detection of target material associated with the health condition; c) a testing zone fluidly coupled to the reaction zone and including one or more testing substances corresponding to the target material; and d) a control zone including a control substance retained at the control zone. The system and methods can be adapted for assessment of sexual health of one or more subjects, in relation to pregnancy, fertility, and/or sexually transmitted infections caused by one or more agents including, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Treponema pallidum, Gardnerella vaginitis, human immunodeficiency virus, human papillomavirus infection, Hepatitis B, and herpes simplex virus.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Application No.PCT/US2019/016064, filed on Jan. 31, 2019, which claims the benefit ofU.S. Provisional Application Ser. No. 62/626,010 filed Feb. 3, 2018 andU.S. Provisional Application Ser. No. 62/768,618 filed Nov. 16, 2018,all of which are incorporated herein by reference in their entirety forall purposes.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted via EFS-Web and is hereby incorporated herein by reference inits entirety. Said ASCII copy, created on Sep. 9, 2019, is named42433_US_Sequence_Listing_ST25_REVISED.txt, and is 346,778 bytes insize.

BACKGROUND

The invention(s) described relate generally to systems and methods forreliably and efficiently assessing sexual health of a subject.Embodiments of the invention(s) described relate to consumer testdevices and kits that can be used to detect the presence of one or moreinfections caused by a sexually transmitted pathogen, optionally inconjunction with the detection of the pregnancy, fertility, and/or othersexual health conditions. Methods for producing the system(s) describedare also described.

Sexually transmitted infections (STIs) remain an important focus areafor global public health. There are over 1 million sexually transmittedinfections (STIs) that are acquired each day and the numbers are growingas 75% of people infected are asymptomatic. However, a high morbidity isassociated with STIs, such as the sequelae of reproductive tractinfections, cervical cancer, congenital syphilis, ectopic pregnancy andinfertility, as well as the morbidity of HIV-related illness and deathfrom acquired immunodeficiency syndrome (AIDS). For example, pregnantwomen can be infected with sexually transmitted infections (STIs). STIscan complicate pregnancy and may have serious effects on both thepregnant individual and the developing baby. Some of these problems maybe seen at birth; however, others may not be discovered until months oryears later. In addition, it is well known that having an STI can makeit easier for a person to get infected with HIV. A global need for aconsumer sensitive and specific rapid test has been established toprevent ectopic pregnancies, pelvic inflammatory disease, infertilityand in some cases death.

SUMMARY

The ability to rapidly and reliably assess health (e.g., sexual health)of a subject who is remote from a clinical setting can aid in earlydetection of abnormal health states. Design of system kit components tofacilitate use by an end-user (e.g., in relation to sample provision andprocessing samples), as well as development of assay components thatstreamline sample processing to extract target material for single andmultiplexed assays can enable such early detection, and thus preventhealth complications. The system(s) and method(s) described hereininclude system components, assay materials, and additional elements forenabling rapid and reliable characterizations of one or more healthconditions (e.g., sexual health conditions) of a subject.

In particular, embodiments of the invention(s) described can outperformexisting tests for detection of sexual health statuses, in relation tocomprehensively and efficiently testing for a panel of differentpathogens in a streamlined format. In examples, embodiments of theinvention can efficiently test for statuses of infections associatedwith the following agents in uni-plex and/or multiplexed formats:Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis,Treponema pallidum, Gardnerella vaginitis, Candida Albicans, Mycoplasmagenitalium, human immunodeficiency virus, human papillomavirusinfection, Hepatitis B, and herpes simplex virus. Embodiments of theinvention(s) also produce increased sensitivity and/or specificity intest results by incorporating multiple test lines associated withdifferent target material regions of the agents/biomarkers assessed.Embodiments of the invention(s) also assess other sexual healthconditions (e.g., statuses of pregnancy, statuses of fertility).

Embodiments of the invention(s) described also include custom extractionand processing buffer compositions that facilitate easy of sampleprocessing, especially in a consumer kit format. Embodiments of theinvention(s) described also include effective reaction and testingsubstance compositions (e.g., aptamers, antibodies, etc.) that produceappropriate binding characteristics with sample target material and donot cross react, thereby enabling multiplexed format testing.

In one or more embodiments, a system for detecting status of a healthcondition (e.g., health condition caused by an agent) includes: a signaloutput device including a) a loading zone; b) a reaction zone fluidlycoupled to the loading zone and including: i) a first reaction substanceconjugated to a first label, where the first substance is notimmobilized and binds to a specific region of a first target of materialof the agent; c) a testing zone fluidly coupled to the reaction zone andincluding: i) a first testing substance retained at the testing zone andthat specifically binds to the first target of material of the agent;and d) a control zone including a control substance retained at thecontrol zone, and where the control substance does not preferentiallycouple to material of the agent. In related embodiments, the reactionzone can optionally include a second reaction substance conjugated to asecond label, where the second reaction substance binds to a secondtarget of material of the agent. In related embodiments, the testingzone can optionally include a second testing substance, where the secondtesting substance is retained at the testing zone and preferentiallybinds to the second target material of the agent. Related to thesystem(s), methods for detecting a health status of a subject include:a) collecting a sample from an individual; b) extracting target materialof the sample, and receiving the target material into a signal outputdevice which processes the target material and outputs a signal relatedto the health status.

One or more embodiments of the invention(s) described include devicesand apparatus for detecting the presence of a sexually transmittedinfection caused by one or more agents including, for example, Chlamydiatrachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Treponemapallidum, Gardnerella vaginitis, Candida Albicans, Mycoplasmagenitalium, human immunodeficiency virus, human papillomavirusinfection, Hepatitis B, and herpes simplex virus. Extractioncompositions for processing samples containing such agents, as well asreaction substances and test substances for enabling detection of suchagents are also described. Furthermore, system configurations formultiplexed assays are described.

One or more embodiments of the invention(s) described include devicesand apparatus for detecting the presence of a sexually transmittedinfection caused by one or more agents, optionally in conjunction withthe detection of pregnancy and/or fertility. Such embodiments enablecomprehensive characterization of sexual health of a subject.

Additional system elements, including sampling kit components withsample collecting tools are also described where, in embodiments, samplecollecting tools are configured to collect a body fluid and/or tissuesample (e.g., a mucosa tissue sample, a urine sample, a blood sample,etc.). In some embodiments, the sample includes vaginal discharge orpenile discharge for sexual health analysis.

The system(s) and method(s) described herein can be adapted to be usedby subjects who are remote from a research or clinical environment, in amanner that is quick and convenient for the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A depicts a system environment for assessing health of a subject,in accordance with one or more embodiments.

FIG. 1B depicts an expanded schematic of system components shown in FIG.1A.

FIG. 2 depicts signal output device portions in accordance with one ormore embodiments.

FIG. 3A depicts a schematic of a first embodiment of a signal outputdevice for multiplexed analyses.

FIG. 3B depicts a schematic of a second embodiment of a signal outputdevice for multiplexed analyses.

FIG. 3C depicts a schematic of a second embodiment of a signal outputdevice for multiplexed analyses.

FIG. 4 depicts an embodiment of kit components configured to adjustsample extraction and processing parameters.

FIG. 5 depicts a flowchart of a method for assessing health of asubject, in accordance with one or more embodiments.

FIG. 6 depicts a schematic of a method for providing and processing asample, in accordance with one or more embodiments.

FIG. 7A depicts a phase of usage of system components, in accordancewith the methods shown in FIGS. 5 and 6.

FIG. 7B depicts another phase of usage of system components, inaccordance with the method shown in FIGS. 5 and 6.

FIG. 7C depicts a phase of usage of an alternative embodiment of systemcomponents, in accordance with the methods shown in FIGS. 5 and 6.

FIG. 7D depicts another phase of usage of an alternative embodiment ofsystem components, in accordance with the method shown in FIGS. 5 and 6.

The figures depict various embodiments of the present invention forpurposes of illustration only. One skilled in the art will readilyrecognize from the following discussion that alternative embodiments ofthe structures and methods illustrated herein may be employed withoutdeparting from the principles of the invention described herein.

DETAILED DESCRIPTION 1. System

FIG. 1A depicts a system environment for assessing health of a subject,in accordance with one or more embodiments. The system 100 shown in FIG.1A includes: a sampling kit 110 including an extraction container 120containing an extraction buffer 125 for extracting a target materialassociated with the health condition; a recessed surface 130 (e.g., of aportion of the sampling kit 110) defining a retained orientation 121 forthe extraction container 120; and a signal output device 140, where thesignal output device 140 includes: a loading zone 145 insertable intothe extraction container 120; a reaction zone 150 fluidly coupled to theloading zone 145 and including at least one reaction substance thatpreferentially couples to the target material; a testing zone 160fluidly coupled to the reaction zone and including at least one testingsubstance retained at the testing zone, where the testing substance(s)preferentially couple(s) to the target material; and a control zone 170including a control substance retained at the control zone, where thecontrol substance does not preferentially couple to the target material.

The system 100 provides one or more consumer test device and kitcomponents that can be used to detect, in a uni-plexed and/ormultiplexed manner, the presence of one or more infections caused by oneor more agents (e.g., sexually transmitted pathogens), optionally inconjunction with characterization of other sexual health conditions(e.g., pregnancy, fertility, etc.). In embodiments, the agent(s) caninclude one or more of (or strains of): Chlamydia trachomatis, Neisseriagonorrhoeae, Trichomonas vaginalis, Treponema pallidum, Gardnerellavaginitis, Candida Albicans, Mycoplasma genitalium, humanimmunodeficiency virus, human papillomavirus infection, Hepatitis B, andherpes simplex virus. Other embodiments can additionally oralternatively target other agents (e.g., non-viral agents, viral agents)in relation to detection of other health conditions states.

FIG. 1B depicts an expanded schematic of system components shown in FIG.1A. As shown in the process flow of FIG. 1B, individual regions of thesampling kit 110 are configured to enable different phases of sampleprocessing in order to provide one or more output signals that can beused to reliably and rapidly characterize health statuses of thesubject. In relation to the extraction container 120 and the extractionbuffer 125, the extraction buffer 125, upon contacting a sample from thesubject, is configured to extract target material (e.g., targetmaterials 101 a and 101 b) associated with the health condition(s) ofinterest. Target materials 101 a and 101 b can be associated withdifferent regions of the same or different agents (e.g., infectiousagents). When received into the loading zone 145 of the signal outputdevice 140, the target material flows to the reaction zone 150, wherethe reaction zone 150 includes a first reaction substance 102 aconjugated to a first label 103 a, wherein the first reaction substance102 a preferentially couples to a first target of target material 101 a.The reaction zone 150 can optionally include a second reaction substance102 b conjugated to a second label 103 b, where the second reactionsubstance 102 b preferentially couples to a second target of targetmaterial 101 b. In an embodiment, the first reaction substance 102 a andthe second reaction substance 102 b are not immobilized within thereaction zone 150. In embodiments, the reaction zone 150 can includemore than two reaction substances conjugated to respective labels, inrelation to assays performed on different types of target material(e.g., related to different health conditions).

As shown in the process flow of FIG. 1B, target material-reactionsubstance complexes flow from the reaction zone 150 to the testing zone160, where the testing zone 160 includes a first testing substance 104 aretained at a first region of the testing zone 160, where the firsttesting substance 104 a preferentially couples to the first target oftarget material 101 a. The testing zone 160 can optionally include asecond testing substance 104 b retained at a second region of thetesting zone 160, where the second testing substance 104 bpreferentially couples to the second target of target material 101 b. Inan embodiment, the first testing substance 104 a and the second testingsubstance 104 b are thus immobilized within the reaction zone 150, andthe first and the second regions, as shown in FIG. 1B, are test lineswithin the testing zone 160. However, the first and the second regionscan alternatively be defined in another manner (e.g., as dots, as areas,as patterns, etc.) within the testing zone 160. Furthermore, inembodiments, the testing zone 160 can include more than two testingsubstances, in relation to assays performed on different types of targetmaterial (e.g., related to different health conditions).

As shown in the process flow of FIG. 1B, sample material including thetarget material and/or other material flows from the testing zone 160 tothe control zone 170, which includes a control substance 105 retained atthe control zone 170, where the control substance 105 does notpreferentially couple to the target material and/or binds to anysubstance (e.g., binds non-specifically to different materials). Assuch, the control substance 105 is immobilized at the control zone 170and can be immobilized along a line of the control zone 170 or inanother manner (e.g., as a dot, as an area, as a pattern).

As shown in FIGS. 1A and 1B, the loading zone 145, the reaction zone150, the testing zone 160, and the control zone 170 are fluidly coupled.In embodiments, adjacent zones can overlap; however, in otherembodiments, one or more adjacent zones of the signal output device 140may not overlap. Furthermore, as shown in FIGS. 1A and 1B, the samplingkit 110 includes a process mode 122 where, in the process mode 122, theextraction container 120 is retained at the surface 130 in the retainedorientation 121, the loading zone 145 is inserted into the extractioncontainer 120, and a sample generated upon extraction of an agent by theextraction buffer 125 flows against gravity through the loading zone145, the reaction zone 150, the testing zone 160, and the control zone170. The retained orientation 121 thus positions the extractioncontainer vertically, such that the sample flows against gravity;however, in alternative embodiments, the retained orientation 121 can bea non-vertical orientation.

In more detail, the recessed surface 130 can be a recessed surface of aportion of a component (e.g., housing, packaging, additional element,etc.) of the sampling kit 110, where the recessed surface 130 iscomplementary to an exterior surface of the extraction container 120. Assuch, the recessed surface 130 is configured to receive the extractioncontainer 120 with the extraction buffer 125, and to hold it in place sothat a user can easily place the signal output device 140 in theextraction container 120 during testing in a consumer environment. Therecessed surface 130 thus provides the retained orientation 121 of thesampling kit, by retaining the extraction container 120 in positionwhile it is in contact with the signal output device 140 during testing.The recessed surface 130 can thus be semi-spherical or of anothermorphology (if the corresponding region of the extraction container 120is semi-spherical or of another morphology). Additional embodiments ofsystems including a recessed surface are described in more detail belowin relation to FIGS. 6 and 7A.

1.1 System—Applications to Specific STIs

1.1.1 Chlamydia trachomatis

In one embodiment, the system 100 is configured to detect presence ofChlamydia trachomatis from a sample acquired from the subject, such thatthe target material (e.g., embodiments of target material 101 a and 101b) includes one or more specific regions of biological material (e.g.,tissue content, cellular content, protein content, amino acid content,nucleic acid content, etc.) of Chlamydia trachomatis, the reactionsubstances (e.g., embodiments of reaction substances 102 a and 102 b)are configured to bind to specific regions of Chlamydia trachomatis,and/or the testing substances (e.g., embodiments of testing substances104 a and 104 b) are configured to bind to specific regions of Chlamydiatrachomatis.

In specific examples of this embodiment, the target material ofChlamydia trachomatis includes individual proteins (and homologs) or acocktails of proteins (and homologs) including one or more of: UniprotID numbers: P26623 (SEQ ID NO 1), A0A0E9CJA7 (SEQ ID NO 2), PODJI1 (SEQID NO 3), O84760 (SEQ ID NO 4), P06597 (SEQ ID NO 5), P0C0Z8 (SEQ ID NO6), A0A0E9CNK8 (SEQ ID NO 7), A0A0E9FM59 (SEQ ID NO 8), B0B7W6 (SEQ IDNO 19), B0B7N4 (SEQ ID NO 20), G4NM26 (SEQ ID NO 21), and P23603 (SEQ IDNO 22). Additionally or alternatively, in specific examples, the targetmaterial of Chlamydia trachomatis includes lipoglycans orlipopolysaccharides of the Chlamydia trachomatis species.

In specific examples of this embodiment, the reaction substances and/ortesting substances configured for detection of Chlamydia trachomatisinclude individual or a cocktail of deoxyribonucleic acid (DNA)-basedaptamers or any permutation of the sequences listed in TABLE 1 and/orindividual or a cocktail of antibody clones listed in TABLE 1.

TABLE 1  Aptamers and Antibodies for Chlamydia trachomatis TypeSequence/Identifier Aptamer AGGGGGCAGGGGGGTTGACTTTACCTTATGCTTAAAGGGGGTGGGCTCGGGAAGAT (SEQ ID NO 12) AptamerAGGGGGAGAACGGGGGGGCTTGGGTTGGGGATGGAT GTGGGAGGCCGGTCGAGAT (SEQ ID NO 13)Aptamer TGGCGCGGACGTACTGGCGAATTGGTGAGCCTCGGGCTGGGTGGGGGGTTAGGGAGAT (SEQ ID NO 14) Antibody Clone M4020310Antibody Clone M2103128 Antibody Clone M61872 Antibody Clone M61871Antibody Clone M4020311 Antibody Clone HM215 Antibody Clone HM031Antibody Clone 9L102 Antibody Clone B351M. CL13-256.2.1 Antibody CloneCT 6703 SP-5 Antibody Clone CT 6701 SP-5 Antibody Clone CT 6709 SP-5Antibody Clone CL21-335.2.3 Antibody Clone 027-10347

In related embodiments, aptamers (e.g., aptamers listed in TABLE 1) fordetection of Chlamydia trachomatis are modified by a biotin or —SH groupor any other modification at the 5′ and/or 3′ terminal of the aptamer.

1.1.2 Neisseria gonorrhoeae

In one embodiment, the system 100 is configured to detect presence ofNeisseria gonorrhoeae from a sample acquired from the subject, such thatthe target material (e.g., embodiments of target material 101 a and 101b) includes one or more specific regions of biological material (e.g.,tissue content, cellular content, protein content, amino acid content,nucleic acid content, etc.) of Neisseria gonorrhoeae, the reactionsubstances (e.g., embodiments of reaction substances 102 a and 102 b)are configured to bind to specific regions of Neisseria gonorrhoeae,and/or the testing substances (e.g., embodiments of testing substances104 a and 104 b) are configured to bind to specific regions of Neisseriagonorrhoeae.

In specific examples of this embodiment, the target material ofNeisseria gonorrhoeae includes individual proteins (and homologs) or acocktails of proteins (and homologs) including one or more of: UniprotID numbers: P95359 (SEQ ID NO 23), A0A1D3HF49 (SEQ ID NO 24), P05430(SEQ ID NO 25), Q02219 (SEQ ID NO 26), Q51006 (SEQ ID NO 27), Q5F942(SEQ ID NO 28), B4RQH9 (SEQ ID NO 29), Q5F6W5 (SEQ ID NO 30), P29842(SEQ ID NO 31), Q5F542 (SEQ ID NO 32), B4RLT9 (SEQ ID NO 33), D6H5Z3(SEQ ID NO 34), and Q5F651 (SEQ ID NO 35); and GenBank/NCBI AccessionNumbers: YP_208979.1 (SEQ ID NO 75), KXI24787.1 (SEQ ID NO 76),SCW17313.1 (SEQ ID NO 77), YP_209073.1 (SEQ ID NO 78), and YP_209148.1(SEQ ID NO 79). In some embodiments, the target material of Neisseriagonorrhoeae includes lipoglycans or lipopolysaccharides of the Neisseriagonorrhoeae species.

In specific examples of this embodiment, the reaction substances and/ortesting substances configured for detection of Neisseria gonorrhoeaeinclude individual or a cocktail of deoxyribonucleic acid (DNA)-basedaptamers or any permutation of the sequences listed in TABLE 2 and/orindividual or a cocktail of antibody clones listed in TABLE 2.

TABLE 2  Aptamers and Antibodies for Neisseria gonorrhoeae TypeSequence or Identifier Aptamer CTCACACTATTTTTTGGCATAGGTGTCGAGGGTGGACGGGGCGGGGCGGTGAGAT (SEQ ID NO 15) AptamerGAGTTAAGTTTGAGTGTTGTCGAGGGTGGACGGGGT GGGGCAAGCTAGTGTGAGAT (SEQ ID NO 16)Antibody Clone M2110186 Antibody Clone M1709NG1 Antibody Clone M1709NG2Antibody Clone 386/418 Antibody Clone M86954 Antibody Clone 20-NR08Antibody Clone 15B441 Antibody Clone 17E95

In related embodiments, aptamers (e.g., aptamers listed in TABLE 2) fordetection of Neisseria Gonorrhoeae are modified by a biotin or —SH groupor any other modification at the 5′ and/or 3′ terminal of the aptamer.

1.1.3 Trichomonas vaginalis

In one embodiment, the system 100 is configured to detect presence ofTrichomonas vaginalis from a sample acquired from the subject, such thatthe target material (e.g., embodiments of target material 101 a and 101b) includes one or more specific regions of biological material (e.g.,tissue content, cellular content, protein content, amino acid content,nucleic acid content, etc.) of Trichomonas vaginalis, the reactionsubstances (e.g., embodiments of reaction substances 102 a and 102 b)are configured to bind to specific regions of Trichomonas vaginalis,and/or the testing substances (e.g., embodiments of testing substances104 a and 104 b) are configured to bind to specific regions ofTrichomonas vaginalis.

In specific examples of this embodiment, the target material ofTrichomonas vaginalis includes individual proteins (and homologs) or acocktails of proteins (and homologs) including one or more of:NCBI/GenBank Accession numbers: EAX87747.1 (SEQ ID NO 41), EAY21310.1(SEQ ID NO 42), EAX96596.1 (SEQ ID NO 43), EAY19137.1 (SEQ ID NO 44),EAY01676.1 (SEQ ID NO 45), EAX86868.1 (SEQ ID NO 46), EAX98121.1 (SEQ IDNO 47), EAY18961.1 (SEQ ID NO 48), AAA91133.1 (SEQ ID NO 49), AAC48339.1(SEQ ID NO 50), and AAC72899.1 (SEQ ID NO 51). In some embodiments, thetarget material of Trichomonas vaginalis includes lipoglycans orlipopolysaccharides of the Trichomonas vaginalis species.

In specific examples of this embodiment, the reaction substances and/ortesting substances configured for detection of Trichomonas vaginalisinclude individual or a cocktail of deoxyribonucleic acid (DNA)-basedaptamers or any permutation of the sequences listed in TABLE 3 and/orindividual or a cocktail of antibody clones listed in TABLE 3.

TABLE 3  Aptamers and Antibodies for Trichomonas vaginalis TypeSequence or Identifier Aptamer TTTATGAGTATATTTCACAATATTTAGTCAGCCATGACCGGTGCAGTGTGTTCAGAGA  (SEQ ID NO 9) AptamerATTCACTCGTCGGGAAACTATGGGCGTACGGTGCT CGGTTTCCTTCTCTCTGAGTAGA(SEQ ID NO 10) Aptamer ATTGGGGGCGGGAGGGGGATGGCGGAGGTTTGTTGTCTGTTCGGGGAGCTGTGTAAGA  (SEQ ID NO 11) Antibody Clone M1011403Antibody Clone A19G Antibody Clone Q65G Antibody Clone BDI675Antibody Clone B985M Antibody Clone B986M Antibody Clone 15B485Antibody Clone 12K238 Antibody Clone M1011401 Antibody Clone M1011404Antibody Clone 15B483In related embodiments, aptamers (e.g., aptamers listed in TABLE 3) fordetection of Trichomonas vaginalis are modified by a biotin or —SH groupor any other modification at the 5′ and/or 3′ terminal of the aptamer.

1.2 System—Uniplexed and Multiplexed Variations

FIG. 2 depicts signal output device portions in accordance with one ormore embodiments of the system shown in FIGS. 1A and 1B. As shown inFIG. 2, the system can be configured to indicate statuses of differenthealth conditions in a uni-plexed or a multiplex manner. For each of aset of health conditions (e.g., sexual health conditions), the systemcan be configured to test a sample for presence of different agentsassociated with the different health conditions. For instance, for afirst health condition, the system can include a signal output device240 including a first reaction zone 250 a with at least one reactionsubstance that preferentially couples to target material associated withthe first health condition; a first testing zone 260 a fluidly coupledto the first reaction zone 250 a and including at least one testingsubstance retained at the first testing zone 260 a, where the testingsubstance(s) preferentially couple(s) to the target material; and acontrol zone 270 including a control substance retained at the controlzone 270, where the control substance does not preferentially couple tothe target material. The first testing zone 260 a includes multipleregions including a first region 265 a, a second region 265 b, and athird region 265 c. The first region 265 a, second region 265 b, andthird region 265 c can include the same or different testing substances(e.g., such as the testing substances described in each of TABLES 1-3),to produce output signals that provide for improved characterization ofstatus of the first health condition (e.g., in relation to sensitivityand specificity of an assay). For instance, in relation to the firsthealth condition, if the sample includes target substances of interestassociated with the first health condition, the first, second, and thirdregions 265 a, 265 b, and 265 c of the first testing zone 260 a can beconfigured to indicate a positive test result (e.g., with opticaldetection of a signal generated at respective regions of the control andtesting zones), with greater sensitivity and specificity than if thefirst testing zone 260 a had a single region. However, in alternativeembodiments, the first testing zone 260 a can additionally oralternatively include fewer or more than three regions.

Also shown in FIG. 2, for a second health condition, the system caninclude a second reaction zone 250 b with at least one reactionsubstance that preferentially couples to target material associated withthe second health condition; and a second testing zone 260 b fluidlycoupled to the second reaction zone 250 b and including at least onetesting substance retained at the second testing zone 260 a, where thetesting substance(s) preferentially couple(s) to the target materialassociated with the second health condition. Similarly, for an nthhealth condition, the system can include an nth reaction zone 250 n withat least one reaction substance that preferentially couples to targetmaterial associated with the nth health condition; and an nth testingzone 260 n fluidly coupled to the nth reaction zone 250 n and includingat least one testing substance retained at the nth testing zone 260 n,where the testing substance(s) preferentially couple(s) to the targetmaterial associated with the nth health condition.

In various applications, and as described above, the set of healthconditions can be associated with STIs associated with one or more of:Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis,Treponema pallidum, Gardnerella vaginitis, Candida Albicans, Mycoplasmagenitalium, human immunodeficiency virus, human papillomavirusinfection, Hepatitis B, and herpes simplex virus. The set of healthconditions can also include non-infection-related health conditionsassociated with sexual health, such as fertility states and pregnancystates, as detected with appropriate biomarkers. Additionally oralternatively, the set of health conditions can include healthconditions not related to sexual health.

1.2.1 Multiplexed Embodiments

FIG. 3A depicts a schematic of an embodiment of a signal output devicefor multiplexed analyses. As shown in FIG. 3A, the system can include asingle signal output device 340 a that includes multiple substrates,each of the substrates configured for characterization of an individualhealth condition. As shown in FIG. 3A, substrate 341 a is configured forassessment of a first health condition, substrate 341 b is configuredfor assessment of a second health condition, and substrate 341 c isconfigured for assessment of a third health condition, where thesubstrates 341 a-341 c process sample material in parallel andindividually output signals for characterizing statuses of theirrespective health conditions. As such, reaction zones and testing zonescorresponding to each health condition can be fluidly isolated from eachother in different pathways. For instance, substrates 341 a and 341 band be configured to detect different STIs, and substrate 341 c can beconfigured to characterize a state of pregnancy. In more detail, usingsubstrate 341 c, substrate 341 c includes a reaction zone 350 a with atleast one reaction substance that preferentially couples to targetmaterial associated with the third health condition; a testing zone 360a fluidly coupled to the reaction zone 350 a and including at least onetesting substance retained at the testing zone 360 a, where the testingsubstance(s) preferentially couple(s) to the target material associatedwith the third health condition; and a control zone 370 a including acontrol substance retained at the control zone 370 a, where the controlsubstance does not preferentially couple to the target materialassociated with the third health condition. Substrate 341 a andsubstrate 341 b also include similar reaction zones and testing zonesconfigured for their respective health conditions, where healthcondition statuses, during use of the signal output device 340 a, areindicated individually from the testing zone and the control zone foreach substrate. In embodiments related to the embodiment shown in FIG.3A, given that the extraction buffer composition (described in moredetail in Section 1.3 below) operates to extract target materialassociated with many health conditions in a single-step mode ofoperation (e.g., upon contacting a biological sample from a subject),the embodiment of the signal output device 340 a shown in FIG. 3A caninclude a shared loading zone 345 fluidly coupled to the reaction zonesof each substrate (i.e., substrates 341 a, 341 b, and 341 c). Duringsample processing, target material associated with each health conditionis extracted using the same extraction buffer, and the extracted targetmaterial flows through the shared loading zone 345 to individualreaction zones of each substrate. However, as shown in FIG. 3A, eachsubstrate (i.e., substrates 341 a, 341 b, and 341 c) can include aloading zone that is distinct from the loading zones of the othersubstrates.

FIG. 3B depicts a schematic of another embodiment of a signal outputdevice 340 b for multiplexed analyses. As shown in FIG. 3B, the signaloutput device 340 b includes a loading zone 345 b and a reaction zone350 b fluidly coupled to the loading zone 345 b, where the reaction zone350 b includes reaction substances that preferentially couple to targetmaterial associated with each of a first health condition, a secondhealth condition, and a third health condition. For instance, the signaloutput device 340 b includes reaction substances that can each bind toone or more specific regions of target material of different pathogensor biomarkers (e.g., of sexual health). In examples, the reaction zone350 b can include non-immobilized aptamers and/or antibodies listed inTABLES 1-3, such that a sample that has undergone extraction can flowthrough the reaction zone 350 b and individual units of target materialassociated with each health condition can bind with their respectivereaction substances before flowing to the testing zone 360 b. Thetesting zone 360 b shown in FIG. 3B includes a first region associatedwith the first health condition, a second region associated with thesecond health condition, and a third region associated with the thirdhealth condition. In order to provide detectable results, testingsubstances associated with the first health condition are immobilized atthe first region, testing substances associated with the second healthcondition are immobilized at the second region, and testing substancesassociated with the third health condition are immobilized at the thirdregion, such that test results (e.g., positive or negative test results)can be observed using the testing zone 360 b in a manner thatdifferentiates results for each health condition. As such, reactionzones and testing zones corresponding to each health condition can befluidly coupled to each other. The signal output device 340 b shown inFIG. 3B also includes a control zone 370 b including a control substanceretained at the control zone 370 b, where the control substance does notpreferentially couple to and is non-specific to target materialassociated with any of the health conditions. In related embodiments,given that the extraction buffer composition (described in more detailin Section 1.3 below) operates to extract target material associatedwith many health conditions in a single-step mode of operation (e.g.,upon contacting a biological sample from a subject), and given that thereaction and testing substances used in relation to the system of FIG.3B are configured to not cross-react, assessments of multiple healthconditions can be performed using a single substrate of a signal outputdevice 340 b.

FIG. 3C depicts a schematic of another embodiment of a signal outputdevice 340 c for multiplexed analyses. As shown in FIG. 3C, the signaloutput device 340 c includes a first side (e.g., front side) and asecond side (e.g., back side), where each side is associated with adifferent health condition (e.g., a first health condition and a secondhealth condition). The signal output device 340 c includes a a loadingzone 345 c and reaction zones (not shown) fluidly coupled to the loadingzone 345 c, where the reaction zones individually include reactionsubstances that preferentially couple to target material associated witheach of a first health condition and a second health condition. Thereaction zone associated with the first health condition can be locatedat the first side of the signal output device 340 c (e.g., within aninternal cavity of a housing of the signal output device 340 c), and thereaction zone associated with the second health condition can be locatedat the second side of the signal output device 340 c (e.g., within aninternal cavity of a housing of the signal output device 340 c). Inexamples, the reaction zone 350 b can include non-immobilized aptamersand/or antibodies listed in TABLES 1-3, such that a sample that hasundergone extraction can flow through the reaction zone 350 b andindividual units of target material associated with each healthcondition can bind with their respective reaction substances beforeflowing to the testing zone 360 c. The testing zone 360 c shown in FIG.3C includes a first side associated with the first health condition anda second side associated with the second health condition. In order toprovide detectable results, testing substances associated with the firsthealth condition are immobilized at the first side and testingsubstances associated with the second health condition are immobilizedat the second side, such that test results (e.g., positive or negativetest results) can be observed using the testing zone 360 c in a mannerthat differentiates results for each health condition. Each sideincludes a window (e.g., windows 380 a and 380 b) that enablesobservation of test results associated with each side of the testingzone 360 c, as relevant to analyses of statuses of each of the firsthealth condition and the second health condition. In relatedembodiments, given that the extraction buffer composition (described inmore detail in Section 1.3 below) operates to extract target materialassociated with many health conditions in a single-step mode ofoperation (e.g., upon contacting a biological sample from a subject),and given that the reaction and testing substances used in relation tothe system of FIG. 3C are configured to not cross-react, assessments ofmultiple health conditions can be performed within a single signaloutput device 340 c, for instance, using different sides of a singlesubstrate housed within the signal output device 340 c.

1.2.2 Examples of Multiplexed Configurations with Specific HealthConditions

In relation to of multiplexed configurations, examples of configurationsfor simultaneously assessing multiple health conditions (e.g., sexualhealth conditions) are described below:

In one example, an embodiment of a signal output device can indicatepresence of Chlamydia trachomatis in conjunction with the presence ofpregnancy, using a single or multiple substrates of a signal outputdevice to indicate Chlamydia trachomatis infection status independentlyof pregnancy status. In this example, reaction substances of a reactionzone and testing substances immobilized at a testing zone of the signaloutput device can be selected from TABLE 1 for detection of Chlamydiatrachomatis material. Similarly, reaction substances of a reaction zoneand testing substances immobilized at a testing zone of the signaloutput device can include substances for detection of pregnancybiomarkers.

In another example, an embodiment of a signal output device can indicatepresence of Neisseria gonorrhoeae in conjunction with the presence ofpregnancy, using a single or multiple substrates of a signal outputdevice to indicate Neisseria gonorrhoeae infection status independentlyof pregnancy status. In this example, reaction substances of a reactionzone and testing substances immobilized at a testing zone of the signaloutput device can be selected from TABLE 2 for detection of Neisseriagonorrhoeae material. Similarly, reaction substances of a reaction zoneand testing substances immobilized at a testing zone of the signaloutput device can include substances for detection of pregnancybiomarkers.

In another example, an embodiment of a signal output device can indicatepresence of Trichomonas vaginalis in conjunction with the presence ofpregnancy, using a single or multiple substrates of a signal outputdevice to indicate Trichomonas vaginalis infection status independentlyof pregnancy status. In this example, reaction substances of a reactionzone and testing substances immobilized at a testing zone of the signaloutput device can be selected from TABLE 3 for detection of Trichomonasvaginalis material. Similarly, reaction substances of a reaction zoneand testing substances immobilized at a testing zone of the signaloutput device can include substances for detection of pregnancybiomarkers.

In another example, an embodiment of a signal output device can indicatepresence of a target pathogen infection in conjunction with the presenceof pregnancy, using a single or multiple substrates of a signal outputdevice to indicate the target pathogen infection status independently ofpregnancy status. In this example, reaction substances of a reactionzone and testing substances immobilized at a testing zone of the signaloutput device can be selected based on specific binding to material ofthe target pathogen. Similarly, reaction substances of a reaction zoneand testing substances immobilized at a testing zone of the signaloutput device can include substances for detection of pregnancybiomarkers. In some embodiments, the target pathogen is selected fromChlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis,Treponema pallidum, Gardnerella vaginitis, Candida Albicans, Mycoplasmagenitalium, human immunodeficiency virus (HIV), human papillomavirusinfection (HPV), Hepatitis B virus (HBV) and herpes simplex virus (HSV).

In another example, an embodiment of a signal output device can indicatepresence of Chlamydia trachomatis and Neisseria gonorrhoeae inconjunction with the presence of pregnancy, using a single or multiplesubstrates of a signal output device to indicate Chlamydia trachomatisinfection status, and Neisseria gonorrhoeae infection statusindependently of pregnancy status. In this example, reaction substancesof a reaction zone and testing substances immobilized at a testing zoneof the signal output device can be selected from TABLE 1 for detectionof Chlamydia trachomatis material and TABLE 2 for detection of Neisseriagonorrhoeae material, where the material(s) from TABLE 1 and TABLE 2 aredistinct from each other at respective reaction zones and testing zones.Similarly, reaction substances of a reaction zone and testing substancesimmobilized at a testing zone of the signal output device can includesubstances for detection of pregnancy biomarkers.

In another example, an embodiment of a signal output device can indicatepresence of Chlamydia trachomatis and Trichomonas vaginalis inconjunction with the presence of pregnancy, using a single or multiplesubstrates of a signal output device to indicate Chlamydia trachomatisinfection status, and Trichomonas vaginalis infection statusindependently of pregnancy status. In this example, reaction substancesof a reaction zone and testing substances immobilized at a testing zoneof the signal output device can be selected from TABLE 1 for detectionof Chlamydia trachomatis material and TABLE 3 for detection ofTrichomonas vaginalis material, where the material(s) from TABLE 1 andTABLE 3 are distinct from each other at respective reaction zones andtesting zones. Similarly, reaction substances of a reaction zone andtesting substances immobilized at a testing zone of the signal outputdevice can include substances for detection of pregnancy biomarkers.

In another example, an embodiment of a signal output device can indicatepresence of Neisseria gonorrhoeae and Trichomonas vaginalis inconjunction with the presence of pregnancy, using a single or multiplesubstrates of a signal output device to indicate Neisseria gonorrhoeaeinfection status, and Trichomonas vaginalis infection statusindependently of pregnancy status. In this example, reaction substancesof a reaction zone and testing substances immobilized at a testing zoneof the signal output device can be selected from TABLE 2 for detectionof Neisseria gonorrhoeae material and TABLE 3 for detection ofTrichomonas vaginalis material, where the material(s) from TABLE 2 andTABLE 3 are distinct from each other at respective reaction zones andtesting zones. Similarly, reaction substances of a reaction zone andtesting substances immobilized at a testing zone of the signal outputdevice can include substances for detection of pregnancy biomarkers.

In another example, an embodiment of a signal output device can indicatepresence of Chlamydia trachomatis, Neisseria gonorrhoeae, andTrichomonas vaginalis in conjunction with the presence of pregnancy,using a single or multiple substrates of a signal output device toindicate Chlamydia trachomatis infection status, Neisseria gonorrhoeaeinfection status, and Trichomonas vaginalis infection statusindependently of pregnancy status. In this example, reaction substancesof a reaction zone and testing substances immobilized at a testing zoneof the signal output device can be selected from TABLE 1 for detectionof Chlamydia trachomatis material, TABLE 2 for detection of Neisseriagonorrhoeae material, and TABLE 3 for detection of Trichomonas vaginalismaterial, where the material(s) from TABLE 1, TABLE 2, and TABLE 3 aredistinct from each other at respective reaction zones and testing zones.Similarly, reaction substances of a reaction zone and testing substancesimmobilized at a testing zone of the signal output device can includesubstances for detection of pregnancy biomarkers.

1.3 System—Materials and Additional Components 1.3.1 System—Microfluidicand Sample Driving Variations

In relation to embodiments of the system described above, embodiments ofthe sampling kit (such as sampling kit 110) and/or signal output device(such as signal output device 140) can include a capillary drivenmicrofluidic device (e.g., a lateral flow assay (LFA) based device).Alternatively, embodiments of the sampling kit (such as sampling kit110) and/or signal output device (such as signal output device 140) caninclude a microfluidic device that is not capillary driven. In someembodiments, sample flow can be driven by pressure (e.g., in embodimentswhere the system includes a pump), centrifugal forces, electrokineticforces, or acoustic forces.

In some embodiments, the system is configured for providing “one-step”or “lateral flow” detection of an agent or biomarker in solubilizedextract from a sample acquired from a subject. In particular, aftertarget material of the agent or biomarker has been extracted from thesample, it will be necessary only to apply a volume of the extract tothe loading zone of the signal output device, wait for a predeterminedtime, and thereafter read the assay results without performing anyadditional steps.

1.3.2 System—Samples and Collecting Tool

The samples described herein include any sample that can be obtainedfrom an individual. In some embodiments, the sample can be obtained byan individual without the help of a health care professional, usingembodiments of the kit described. In some embodiments, the sample can beobtained under the guidance of a health care professional.

Non-limiting examples of a sample of this invention can include vaginalfluid, vaginal tissue, vaginal wash, vaginal swab, vaginal discharge,cervical swab, cervical tissue urethral swab, urethral discharge, rectalswab, rectal material, rectal wash, urine, blood, serum, plasma, saliva,tears, skin swab, semen, seminal fluid, sputum, bronchial fluid,bronchial wash, peritoneal fluid, peritoneal wash, pleural fluid,pleural wash, cerebrospinal fluid, eye fluid and/or tissue, fluid and/ortissue from lung, liver, heart, brain, kidney, spleen or muscle and anycombination thereof. In some embodiments, the sample is a blood sample.In some embodiments, the sample is a urine sample. In some embodiments,the sample is a vaginal discharge or a penile discharge. In someembodiments, the sample is obtained from contacting an ulcer in genitalarea.

In some embodiments, a sample is collected in a collection unit. In someembodiments, a sample collection unit is configured to receive a volumeof the bodily fluid sample. In an instance, the sample collection unitis configured to receive a volume of the bodily fluid sample equivalentto a single drop of blood.

In some embodiments, a sample collection unit includes a samplecollecting tool, where the sample collecting tool includes a swab. Insome embodiments, the swab is a vaginal swab or urethral swab. In someembodiments, the swab is an endocervical swab. In some embodiments, thesample collecting tool comprises a fluid collecting container. In someembodiments, the fluid collecting container comprises a tube. In someembodiments, the tube is serum tube or a plasma tube. As described belowin relation to FIGS. 6 and 7C through 7D, in some embodiments, thesample collecting tool (e.g., swab or other collecting tool) can beintegrated with the signal output device. For instance, a swab can beattached to the signal output device in a manner that couples the swabto the sample loading zone (and/or reaction zone) of the signal outputdevice, such that a user can provide a sample to the swab and the swab,integrated with the signal output device, can be transmitted into theextraction container for further sample processing.

In some embodiments, the biological sample of this invention to be usedin the methods of this invention can be diluted 1:2, 1:5, 1:10, 1:100,1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:1500,1:2000, 1:3000, 1:4000, 1:5000, 1:6000, 1:7000, 1:8000, 1:9000,1:10,000, 1:20,000, 1:30,000, 1:40,000, 1:50,000, 1:100,000, etc. Such adilution can be carried out according to protocols well known in theart. In some embodiments, a specific dilution can be used to increasethe specificity and/or sensitivity of the method or device as describedherein.

1.3.3 System—Pathogens and Target Substances

The methods, devices and kits of the present application are intendedfor diagnosing an infection of a sexually transmitted pathogen includingall of the bacteria, viruses and parasites that can be transmittedthrough sexual contact. Exemplary pathogens discussed herein areChlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis,Treponema pallidum, Gardnerella vaginitis, Mycoplasma Genitalium,Candida Albicans (yeast infection), Human immunodeficiency virus (HIV),Human papillomavirus (HPV), Hepatitis C virus (HCV), Hepatitis B virus(HBV), Herpes simplex virus (HSV).

Chlamydia trachomatis (Chlamydia trachomatis) serovars A, B, Ba and Care associated with endemic trachoma, which is the most commonpreventable form of blindness in certain parts of the Mediterranean andMiddle East. Serovars L1, L2 and L3 are associated with lymphogranulomavenereum (LGV) in tropical settings. Serovars D through K causenongonococcal urethritis and epididymitis in men, Reiter's syndrome orproctitis, conjunctivitis in both men and women, and cervicitis,urethritis, endometritis, salpingitis and perihepatitis in women.Between one-half and two-thirds of chlamydial infections in men andwomen may be asymptomatic and remain undiagnosed and untreated. Inwomen, this may lead to late sequelae such as endometritis, salpingitis,pelvic inflammatory disease, ectopic pregnancy or tubal factorinfertility. Chlamydia trachomatis in the cervix may be transmitted to aneonate during vaginal delivery, resulting in conjunctivitis andneonatal pneumonia.

In some embodiments, the target material of Chlamydia trachomatis isexpressed on all strains. In some embodiments, the target substance isexpressed on one or more specific strains. In some embodiments, thetarget substance is a major outer membrane protein of Chlamydiatrachomatis. In some embodiments, the target substance is evenlydistributed on Chlamydia trachomatis. In some embodiments, the targetsubstance is unevenly distributed on Chlamydia trachomatis.

Neisseria gonorrhoeae is an obligate human pathogen and is theetiological agent of gonorrhea. Neisseria gonorrhoeae is a Gram-negativecoffee bean-shaped diplococci bacteria. Syndromes include cervicitis inwomen, and urethritis, pharyngitis and proctitis in both sexes. Ifuntreated, women may experience severe sequelae of pelvic inflammatorydisease, chronic pelvic pain, ectopic pregnancy and tubal infertility,while men may develop epididymitis, prostatitis and urethral stricture.Occasionally, some individuals may develop disseminated infections withsystemic complications, while others may have asymptomatic infectionsand transmit gonococci unknowingly. Oropharyngeal and anorectalgonococcal infections may be acquired by persons practicing receptiveoral or anal intercourse or by contamination from cervical secretions.Occasionally, adults may present with conjunctivitis. In someembodiments, the target material of Neisseria gonorrhoeae includes apeptide or protein comprising any portion or the whole of a sequenceselected from the sequences described herein.

Trichomonas vaginalis (TV) is likely the most common non-viral sexuallytransmitted infection (STI) in the world. It is as an important sourceof reproductive morbidity, a facilitator of HIV transmission andacquisition, and thus it is an important public health problem. Despiteits importance in human reproductive health and HIV transmission, it isnot a reportable disease and surveillance is not generally done. This isproblematic since most persons infected with TV are asymptomatic. Insome embodiments, the target material of Trichomonas vaginalis include apeptide or protein comprising any portion or the whole of a sequenceselected from the sequences described herein.

The target material of an agent or biomarker can be anything that isspecifically expressed by the agent/biomarker or any component of theagent/biomarker. In some embodiments, the target substance is apolynucleotide. In some embodiments, the target substance is an RNA. Insome embodiments, the target substance is an MicroRNA. In someembodiments, the target substance is a DNA. In some embodiments, thetarget substance is a peptide or protein. In some embodiments, thetarget substance comprises a peptide or protein comprising any portionor the whole of a sequence selected from the sequences described hereinin Section X. In some embodiments, the target substance is a lipid. Insome embodiments, the target substance is a polysaccharide. In someembodiments, the target substance is a lipopolysaccharide.

1.3.4 System—Extraction Buffer

In some embodiments, as described above, the extraction buffer isconfigured for “single-step” extraction of target material from one ormore agents associated with health conditions. In some embodiments, theextraction buffer comprises: 1-100% PBS (phosphate buffered saline),1-100% TBS (Tris buffered saline), 1-100% HBS (HEPES buffered saline)and extraction substance. The extraction substance is selected from oneor more substances in this group: 0.01%-100% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate, 0.1%-100% BugBuster™, 0.01%-100%octylthioglucoside, 5-5000 mM sodium hydroxide, 0.01%-100% Triton X-100,0.01%-100% octyl glucoside. In embodiments, the extraction buffer isused at concentration between 0.001% and 100%; however, in alternativeembodiments, the extraction buffer can be used at another concentration.

1.3.5 System—Substrate Materials

In relation to embodiments of the system described above, embodiments ofthe loading zone (such as loading zone 145) can include or be composedof cellulose and/or glass fiber. In some embodiments, the loading zoneis capable of transporting the sample to other parts of the device(e.g., by way of fluid coupling). In some embodiments, thetransportation of the sample through different zones from the loadingzone is in a continuous and/or homogenous manner. In some embodiments,the loading zone includes materials or reagents that pretreat the samplebefore its transportation. In some embodiments, the loading zoneincludes pretreating materials/reagents configured for one or more of:separation of sample components, removal of interfering materials,and/or adjustment of pH.

In relation to embodiments of the system described above, the system caninclude substrate materials and/or structures that provide for lateralflow of a sample from a loading zone to a testing zone (such as testingzone 160). In some instances, the devices include a bibulous material ormember that readily absorbs liquid and provides for liquid flow throughthe member. Examples of bibulous materials include: organic or inorganicpolymers and natural and synthetic polymers. More specific examples ofsuitable solid supports include, without limitation, glass fiber,cellulose, nylon, cross-linked dextran, various chromatographic papersand nitrocellulose. In some embodiments, the bibulous member includes amembrane, and in a specific example, the membrane is a nitrocellulosemembrane. In some embodiments, the membrane is located in testing zoneand/or control line zone, described in more detail below.

While the bibulous member and overall configuration of a lateral flowassay device implemented in embodiments of the system may vary, incertain embodiments the bibulous member can have a strip configuration,some embodiments of which are described in relation to FIGS. 1A-1B, 2,and 3A-3C above. Where the bibulous material is configured as a strip,the bibulous member can have a length that is longer than its width. Insome examples, the length is longer than the width by 1.5 fold or more,such as 2-fold or more, e.g., 10 fold or more, including 20-fold ormore. In some examples, the length of the bibulous member ranges from0.5 to 20 cm, such as 1.0 to 15 cm, e.g., 2.0 to 10 cm, while the widthranges 0.1 to 10.0 cm, such as 0.5 to 2.5 cm, e.g., 1 to 2 cm. Thethickness of the bibulous member may also vary, ranging in someinstances from 0.01 to 0.05 cm, such as 0.1 to 0.4 cm, e.g., 0.1 to 0.25cm.

Optionally, the signal output device of the system can include anabsorbent pad downstream from the reaction zone and any control region,e.g., at the end distal from the sample loading zone, where theabsorbent pad is configured to absorb fluid and reagents present thereinthat have flowed through the bibulous member. While the configuration ofthe absorbent pad may vary, in some instances it is configured to absorba volume of liquid that is substantially the same as the volume ofsample that is applied to the sample loading zone during use.

1.3.6 System—Configuration of Loading Zone

As such, embodiments of the loading zone can include a terminal zone(e.g., a most upstream zone) of the bibulous member, e.g., positionedcloser to one end of the bibulous member. Alternatively, embodiments ofthe loading zone may be distinct from the bibulous member, butconfigured to provide for fluid communication of sample into thebibulous member upon application of sample to the sample loading zone.The loading zone may be configured to receive samples of varyingvolumes, where in some instances the sample zone is configured toreceive a sample having a volume ranging from 0.1 ul to 20 ml such as 5ul to 20 ml.

In some instances, the loading zone may include a metering deviceconfigured to meter a specific amount of sample into the bibulousmember.

1.3.7 System—Configuration of Reaction Zone

Embodiments of the reaction zone can be positioned at some distancedownstream from the loading zone. The distance between the loading zoneand the reaction zone may vary. In some embodiments, the distance rangesfrom 0.1 to 10 cm, such as 0.1 to 3 cm and including 0.5 to 2 cm. Insome embodiments, the reaction zone overlaps with the loading zone in aportion or full. In some embodiments, the reaction zone overlaps withthe loading zone in about 25%, 50%, 75%, and 100%.

As described above, in some embodiments, the reaction substancesimplemented for detection are not immobilized at the reaction zone(s).In relation to immobilization, a substance and the bibulous membermaintain their position relative to each other in space under theconditions of use, e.g., under the assay conditions. As such, a notimmobilized reaction substance is not stably associated with thebibulous member and can migrate under the capillary pressure or otherdrivers of sample flow. In some embodiments, examples of which aredescribed above, a reaction substance binds to a specific region of atarget material of a pathogen or other agent.

In some embodiments (some of which are described above), the reactionzone includes two or more reaction substances that are conjugated to thesame or different labels. In some embodiments, the two or more reactionsubstances are not immobilized. In some embodiments, the two or moresubstances each bind to the same specific region of the same targetmaterial of an agent or biomarker. In some embodiments, the two or moresubstances each bind to two or more different specific regions of thesame target material of an agent or biomarker. In some embodiments, thetwo or more substances each bind to a specific region of two or moredifferent target materials of an agent or biomarker. In someembodiments, the two or more substances each bind to a specific regionof target materials of two or more different agents or biomarkers.

1.3.7.1 System—Reaction Zone Substances

The reaction substances in the reaction zone that bind to specificagent/biomarker regions of target material of interest can include oneor more of: a protein, a peptide or its analogs (e.g., an antibody,antigen, peptoid, D-peptide, beta-peptide), or a nucleic acid (e.g., anaptamer) or its analogs.

Antibodies

In some embodiments, the reaction substances include antibodies. In someembodiments, an antibody used is a monoclonal antibody. In someembodiments, the antibody is a polyclonal antibody. In some embodiments,the antibody is a bispecific antibody that binds to two separate regionsof an agent, or two separate regions of two different agents. In someembodiments, the substance is a fragment or a variant of an antibody(e.g., Fab fragment or single chain variable fragment).

In some embodiments, the reaction substances include monoclonalantibodies that bind to a specific region of target substance on anagent (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonasvaginalis, Treponema pallidum, Gardnerella vaginitis, Mycoplasmagenitalium, Candida Albicans (yeast infection), Human immunodeficiencyvirus (HIV), Human papillomavirus (HPV), Hepatitis C virus (HCV),Hepatitis B virus (HBV), Herpes simplex virus (HSV)). Such monoclonalantibodies can be generated using a hybridoma technique. For example,monoclonal antibodies can be produced from a single B-lymphocyte cloneinvolving immunizing a certain species (e.g., a mouse, rat, rabbit, orgoat) against the specific region on a target substance and obtainingthe B-lymphocytes from the spleen of the species. The B-lymphocytes arethen fused (by chemical- or virus-induced methods) with an immortalmyeloma cell line lacking thehypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene and notcontaining any other immunoglobulin-producing cell. These hybridomacells are then cultured in vitro in selective medium (i.e. mediumcontaining hypoxanthine-aminopterinthymidine) where only the hybridomas(i.e. the fusion between the primary B-lymphocytes and myeloma cells)survive as they have inherited immortality from the myeloma cells andselective resistance from the primary B-lymphocytes (as the myelomacells lack HGPRT, they cannot synthesize nucleotides de novo as this isinhibited by aminopterin in the selective medium). The initial cultureof hybridomas contains a mixture of antibodies derived from manydifferent primary B-lymphocyte clones, each secreting its own individualspecific antibody into the culture medium (i.e. the antibodies are stillpolyclonal). Each individual clone can be separated by dilution intodifferent culture wells. The cell culture medium can then be screenedfrom many hundreds of different wells for the specific antibody activityrequired and the desired B-lymphocytes grown from the positive wells andthen recloned and retested for activity. The positive hybridomas andmonoclonal antibodies generated can then be stored away in liquidnitrogen.

Monoclonal antibodies can also be generated using phage display. Thisinvolves isolating B-lymphocytes from the blood of humans and thenisolating the mRNA and converting it into cDNA using PCR to amplify allthe VH and VL segments. These segments can then be cloned into a vector(usually as scFv) next to the PIII protein of a bacteriophage. Thisvector is then introduced into E. coli cells in order to generate alibrary containing approximately 10¹⁰ clones of antibody fragments. E.coli can then secrete the bacteriophage containing the VH and VLsegments as part of the bacteriophage coat. Specific VH and VL segmentsagainst the target substance can then be selected and used to re-infectE. coli with the bacteriophage. Cells containing the plasmid can then beisolated and sequenced. Its advantages include: once the library ismade, the same library can be used to generate new antibodies and doesnot have to be remade, no immunizations are required as the entireprocess is done in vitro, antibodies can be obtained much more quicklythan the traditional hybridoma technique and the library can be used togenerate antibodies to toxic target substances that could not be used toimmunize an animal.

In some embodiments, monoclonal antibodies can also be improved inmultiple aspects. For example, binding affinity to the target substancecan be improved by using phage display libraries to isolate antibodieswith strong affinities for the target substance.

In some embodiments, monoclonal antibodies are recovered and/or purifiedwith a process comprising one or more of the following steps: 1) harvestantibodies with centrifugation/filgration thereby removing cells andcell debris; 2) protein A and/or protein G chromatograph which yieldshighly purified product in a single step; 3) low pH hold to inactivateendogenous/adventitious viruses; 4) additional chromatography steps tofurther remove impurities and viruses; 5) filtration to further removeendogenous/adventitious viruses; and 6) ultrafiltration/diafiltration.

In some embodiments (some of which are described above), the reactionzone includes reaction substances including antibodies listed in TABLES1, 2, and 3.

Aptamers

In some embodiments, the reaction substance that binds to a specificregion of an agent is an aptamer or aptamers. In some embodiments, theaptamer is generated by an in vitro process known as SELEX (systematicevolution of ligands by exponential enrichment). In some embodiments,the aptamer is an organic molecule.

In some embodiments, the aptamer has a molecular weight of about 50 to100 Da, 50 to 200 Da, 50 to 500 Da, 50 to 1000 Da, 50 to 2,000 Da, 50 to3,000 Da, 50 to 4,000 Da, 50 to 5,000 Da, 50 to 6,000 Da, 50 to 7,000Da, 50 to 8,000 Da, 50 to 9,000 Da, 50 to 10,000 Da, 50 to 11,000 Da, 50to 12,500 Da, 50 to 15,000 Da, 100 to 200 Da, 100 to 500 Da, 100 to 1000Da, 100 to 2,000 Da, 100 to 3,000 Da, 100 to 4,000 Da, 100 to 5,000 Da,100 to 6,000 Da, 100 to 7,000 Da, 100 to 8,000 Da, 100 to 9,000 Da, 100to 10,000 Da, 100 to 11,000 Da, 100 to 12,500 Da, 100 to 15,000 Da, 200Da to 500 Da, 200 to 1000 Da, 200 to 2,000 Da, 200 to 3,000 Da, 200 to4,000 Da, 200 to 5,000 Da, 200 to 6,000 Da, 200 to 7,000 Da, 200 to8,000 Da, 200 to 9,000 Da, 200 to 10,000 Da, 200 to 11,000 Da, 200 to12,500 Da, 200 to 15,000 Da, 500 to 1000 Da, 500 to 2,000 Da, 500 to3,000 Da, 500 to 4,000 Da, 500 to 5,000 Da, 500 to 6,000 Da, 500 to7,000 Da, 500 to 8,000 Da, 500 to 9,000 Da, 500 to 10,000 Da, 500 to11,000 Da, 500 to 12,500 Da, 500 to 15,000 Da, 1,000 to 2,000 Da, 1,000to 3,000 Da, 1,000 to 4,000 Da, 1,000 to 5,000 Da, 1,000 to 6,000 Da,1,000 to 7,000 Da, 1,000 to 8,000 Da, 1,000 to 9,000 Da, 1,000 to 10,000Da, 1,000 to 11,000 Da, 1,000 to 12,500 Da, 1,000 to 15,000 Da, 2,000 to3,000 Da, 2,000 to 4,000 Da, 2,000 to 5,000 Da, 2,000 to 6,000 Da, 2,000to 7,000 Da, 2,000 to 8,000 Da, 2,000 to 9,000 Da, 2,000 to 10,000 Da,2,000 to 11,000 Da, 2,000 to 12,500 Da, 2,000 to 15,000 Da, 3,000 Da to4,000 Da, 3,000 to 5,000 Da, 3,000 to 6,000 Da, 3,000 to 7,000 Da, 3,000to 8,000 Da, 3,000 to 9,000 Da, 3,000 to 10,000 Da, 3,000 to 11,000 Da,3,000 to 12,500 Da, 3,000 to 15,000 Da, 4,000 to 5,000 Da, 4,000 to6,000 Da, 4,000 to 7,000 Da, 4,000 to 8,000 Da, 4,000 to 9,000 Da, 4,000to 10,000 Da, 4,000 to 11,000 Da, 4,000 to 12,500 Da, 4,000 to 15,000Da, 5,000 to 6,000 Da, 5,000 to 7,000 Da, 5,000 to 8,000 Da, 5,000 to9,000 Da, 5,000 to 10,000 Da, 5,000 to 11,000 Da, 5,000 to 12,500 Da,5,000 to 15,000 Da, 6,000 to 7,000 Da, 6,000 to 8,000 Da, 6,000 to 9,000Da, 6,000 to 10,000 Da, 6,000 to 11,000 Da, 6,000 to 12,500 Da, 6,000 to15,000 Da, 7,000 to 8,000 Da, 7,000 to 9,000 Da, 7,000 to 10,000 Da,7,000 to 11,000 Da, 7,000 to 12,500 Da, 7,000 to 15,000 Da, 8,000 to9,000 Da, 8,000 to 10,000 Da, 8,000 to 11,000 Da, 8,000 to 12,500 Da,8,000 to 15,000 Da, 9,000 to 10,000 Da, 9,000 to 11,000 Da, 9,000 to12,500 Da, 9,000 to 15,000 Da, 10,000 to 11,000 Da, 10,000 to 12,500 Da,10,000 to 15,000 Da, or 12,000 to 15,000 Da, each inclusive. In someembodiments, the aptamer has a molecular weight of about 100 to 10,000Da.

In some embodiments (some of which are described above), the reactionzone includes reaction substances including aptamers listed in TABLES 1,2, and 3.

Molecular Beacons

In some embodiments, the reaction substance that binds to a specificregion of an agent includes a molecular beacon or molecular beacons.Molecular beacons are a specific DNA hairpin structure with fluorophoreat one end and quencher at the other end. Fluorophore cannot producefluorescence in the absence of an analyte (e.g., a target substance of apathogen) because of closely located quencher. When complementary DNAsequence (e.g., a target substance of a pathogen) is present as a targetanalyte, stem and loop portions of the beacons are opened as a result ofa force and fluorescence signal is observed. In some embodiments, themolecular beacon binds to a target substance of a pathogen, wherein thetarget substance comprises a nucleic acid, a toxin, and/or a protein orpeptide. In some embodiments, the molecular beacon comprises a loopregion and/or a double stranded stem region. In some embodiments, theloop region is complementary to a target substance (e.g., a DNA, anmRNA, a toxin or a protein of a pathogen).

In some embodiments, the molecular beacon has about 10 to 15, 10 to 20,10 to 25, 10 to 30, 10 to 35, 10 to 40, 10 to 45, 10 to 50, 15 to 20, 15to 25, 15 to 30, 15 to 35, 15 to 40, 15 to 45, 15 to 50, 20 to 25, 20 to30, 20 to 35, 20 to 40, 20 to 45, 20 to 50, 25 to 30, 25 to 35, 25 to40, 25 to 45, 25 to 50, 30 to 35, 30 to 40, 30 to 45, 30 to 50, 35 to40, 35 to 45, 35 to 50, 40 to 45, 40 to 50 or 45 to 50 base pairs in theloop region, each inclusive, wherein the loop is complimentary to atarget substance. In some embodiments, the molecular beacon has about 15to 30 base pairs in the loop, wherein the loop is complimentary to atarget substance.

In some embodiments, the molecular beacon has about 3 to 4, 3 to 5, 3 to6, 3 to 7, 3 to 8, 3 to 9, 4 to 5, 4 to 6, 4 to 7, 4 to 8, 4 to 9, 5 to6, 5 to 7, 5 to 8, 5 to 9, 6 to 7, 6 to 8, 6 to 9, 7 to 8, 7 to 9 or 8to 9 base pairs at the double stranded stem region.

DNA Probes

In some embodiments, the reaction substance that binds to a specificregion of a pathogen includes a DNA probe.

Pregnancy and Fertility Biomarkers

In some embodiments (some of which are described above), the reactionzone further includes a substance that binds to a biomarker ofpregnancy. In some embodiments, the biomarker(s) include one or more of:human chorionic gonadotropin (hCG), activin A, pregnancy-associatedplasma protein-A (PAPP-A), human placental lactogen (hPL), A disintegrinand Metalloprotease-12 (ADAM-12), pregnancy-specific beta glycoprotein 1(SP-1), placental mRNAs, progestrerone, Inhibin A, Vascular EndothelialGrowth Factor (VEGF), Placental-like growth factor (P1GF), LeukemicInhibitory Factor, Glycodelin, Mucin-1, Adrenomedullin, and otherbiomarkers.

In some embodiments (some of which are described above), the reactionzone further includes a substance that binds to a biomarker offertility. In some embodiments, the biomarker(s) include one or more of:oestrone-3-glucuronide (E3G0, luteinizing hormone, follicle stimulatinghormone (FSH), estrogen, progesterone, testosterone,dehydroepiandrosterone (DHEA), cortisol, sex hormone binding globulin(SHBG), triiodothyronine (T3), Thyroxine (T4), thyroid stimulatinghormone (TSH), thyroid peroxidase antibodies (TPO antibodies), and otherbiomarkers.

1.3.7.2 System—Reaction Zone Labels

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include one or more of: gold nanoparticles,colored latex beads, magnetic particles, carbon nanoparticles, cellulosenano beads, selenium nanoparticles, silver nanoparticles, quantum dots,up converting phosphors, organic fluorophores, textile dyes, enzymes,liposomes and labels.

In some embodiments, the conjugation of the substance that binds to aspecific region of a pathogen and the label is stable for at least about1, 3, 5, 7, 10, 12, or 14 or more days. In some embodiments, theconjugation is stable for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10or more weeks. In some embodiments, the conjugation is stable for atleast about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months. Insome embodiments, the conjugation is stable for at least about 1, 2, 3,4, 5, or more months. The conjugation is stable when at least 50%, 60%,70%, 80%, 90%, 95%, 98%, 99%, 99.5% of the conjugates are functional(e.g., labeling the true positive and/or not labeling the falsenegative) and/or at most 30%, 25%, 20%, 15%, 10%, 5%, 2.5%, 1% or 0.5%of the conjugates are not functional (e.g., labeling the false positiveand/or not labeling the true positive).

In some embodiments, the concentration of the label is at least about10⁻¹², 10⁻¹¹, 10⁻¹⁰, 10⁻⁹, 10⁻⁸, 10⁻⁷, or 10⁻⁶ M. In some embodiments,the concentration of the label is at most about 10⁻¹¹, 10⁻¹⁰, 10−9,10⁻⁸, 10⁻⁷, 10⁻⁶, 10⁻⁵ or 10⁻⁴ M. In some embodiments, the concentrationof the label is about 10⁻¹², 10⁻¹¹, 10⁻¹⁰, 10⁻⁹, 10⁻⁸, 10⁻⁷, or 10⁻⁶ M.

In some embodiments, the label is capable of generate a direct signalafter encountering the analyte (e.g., the specific region that theconjugated substance binds to). In some embodiments, the label generatesa signal after an additional step.

In some embodiments, the device comprises more than one label. In someembodiments, the more than one label can be composed of same ordifferent material(s). In some embodiments, the more than one label cangenerate same or different signals.

Cellulose NanoBeads

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include Cellulose NanoBeads. CelluloseNanoBeads (e.g., NanoAc™) are inert and spherical, which have highaffinity to biomolecules and can be functionalized. Cellulose nanobeadsare highly stable, deeply colored particles that have demonstratedappropriate performance.

Latex Beads

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include latex beads. Latex beads are inertand spherical, which have high affinity to biomolecules and can befunctionalized.

Gold Nanoparticles

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include gold nanoparticles. In someembodiments, the gold nanoparticles include colloidal gold. Colloidalgold is inert and spherical, which have high affinity to biomoleculesand can be functionalized. In some embodiments, the average diameter ofthe gold nanoparticles is about 5 to 150 nm. In some embodiments, theaverage diameter of the gold nanoparticles is no greater than 150 nm or200 nm. In some embodiments, the average diameter of the goldnanoparticles is about 40 nm. In some embodiments, the average diameterof the gold nanoparticles is about 30 nm. In some embodiments, theaverage diameter of the gold nanoparticles is about 60 nm. In someembodiments, the average diameter of the gold nanoparticles is about 5to 25, 5 to 50, 5 to 75, 5 to 100, 5 to 125, 5 to 150, 5 to 175, 5 to200, 25 to 50, 25 to 75, 25 to 100, 25 to 125, 25 to 150, 25 to 175, 25to 200, 50 to 75, 50 to 100, 50 to 125, 50 to 150, 50 to 175, 50 to 200,75 to 100, 75 to 125, 75 to 150, 75 to 175, 75 to 200, 100 to 125, 100to 150, 100 to 175, 100 to 200, 125 to 150, 125 to 175, 125 to 200, 150to 175, 150 to 200, or 175 to 200 nm, each inclusive.

Europium Ions

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include Europium ions. In some embodiments,Europium ion is chelated by isothiocyanate. Isothiocyanate can befunctionalized and has high affinity to biomolecules. Europium ions arehighly fluorescent and have demonstrated appropriate performance overstandard labels in lateral flow applications.

Magnetic Particles or Aggregates

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include a magnetic particle or aggregate. Insome embodiments, the magnetic particle or aggregate can produce asignal, wherein the signal can be read by an optical strip reader ormagnetic assay reader. In some embodiments, the magnetic particle oraggregate comprises one or more iron oxide particle. In someembodiments, the one or more iron particles comprise Fe₃O₄ particles. Insome embodiments, the one or more iron oxide particles are modified withpolyethylene glycol. In some embodiments, the one or more iron oxideparticles are crosslinked with poly-L-lysine.

Fluorescent and/or Luminescent Materials

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include a fluorescent or luminescentmaterial. In some embodiments, the label includes an organic fluorophore(e.g., rhodamine). In some embodiments, the label includes a fluorescentmicrosphere. In some embodiments, the label includes a nanomaterial. Insome embodiments, the nanomaterial includes quantum dots. In someembodiments, the quantum dots are encapsuled into a nanobead, therebyimproving the detection sensitivity.

In some embodiments, the labels used include at least two or moredifferent quantum dots, wherein the different quantum dots generatedifferent colors.

In some embodiments, the labels used include upconverting phosphors(UCP). In some embodiments, the UCP are characterized with theirexcitation in infra-red region and emission in high energy visibleregion. In some embodiments, the UCP are characterized with the absenceof auto fluorescence or the absence a significant level of autofluorescence. In some embodiments, the average diameter of UCP is about10 nm to 1 um. In some embodiments, the average diameter of UCP is about10 to 50, 10 to 100, 10 to 200, 10 to 300, 10 to 400, 10 to 500, 10 to750, 50 to 100, 50 to 200, 50 to 300, 50 to 400, 50 to 500, 50 to 750,50 to 1,000, 100 to 200, 100 to 300, 100 to 400, 100 to 500, 100 to 750,100 to 1,000, 200 to 300, 200 to 400, 200 to 500, 200 to 750, 200 to1,000, 300 to 400, 300 to 500, 300 to 750, 300 to 1,000, 400 to 500, 400to 750, 400 to 1,000, 500 to 750, 500 to 1,000, or 750 to 1,000 nm, eachinclusive. In some embodiments, the average diameter of UCP is about 40to 400 nm. In some embodiments, the average diameter of UCP is about 40nm.

In some embodiments, the labels used include fluorescent europiumnanoparticles. In some embodiments, the fluorescent europiumnanoparticles comprise europium III nanoparticles. In some embodiments,the average diameter of europium nanoparticles is about 100 to 1,000 nm.In some embodiments, the average diameter of europium nanoparticles isabout 400 to 600 nm. In some embodiments, the average diameter ofeuropium nanoparticles is about 500 nm (e.g., 520 nm).

In some embodiments, the labels used include silica nanoparticles. Insome embodiments, the label comprises lanthanide chelate-loaded silicananoparticles.

In some embodiments, the labels used include a fluorescent microsphere.

Enzymes

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include an enzyme. In some embodiments, theenzyme is horse-radish peroxidase (HRP). In some embodiments, the enzymeis alkaline phosphatase (AP). In some embodiments, the enzyme is Glucoseoxidase. In some embodiments, the enzyme is Urease. In some embodiments,the amplification of the detectable signal is obtained by reacting theenzyme with one or more substrates or additional enzymes and substratesto produce a detectable reaction product.

Colloidal Carbon

In some embodiments, the labels used (e.g., labels to which reactionsubstances are conjugated) include colloidal carbon. Unstabilized carboncan be used to produce carbon sols suitable for protein adsorption.Their carbon sols are formed by suspending carbon particles ofwell-defined particle sizes in distilled water or low ionic strengthbuffers, sonicated or vigorously agitated, followed by centrifugation.These unstabilized carbon sols were flocculated easily by salt. However,when coated with macromolecules such as antibodies, they were“protected” from flocculation. In practice, increasing amounts of amacromolecule are incubated with a fixed amount of non-stabilized carbonaqueous sol under defined conditions to determine the “minimalprotective amount”. The optimal pH for adsorption can be determined byone of ordinary skill in the art. Unlike colloidal gold, in which theconjugation of protein to colloidal gold is near instantaneous,adsorption onto colloidal carbon takes a longer time from one to severalhours.

Colloidal carbon has appropriate properties in terms of stability andhigh color contrast on a membrane.

1.3.8 System—Configuration of Testing Zone

In some embodiments (some of which are described above), the systemincludes a testing zone. The testing zone can be positioned at somedistance downstream from the reaction zone. The distance between thereaction zone and the testing zone may vary. In some embodiments, thedistance ranges from 0.1 to 10 cm, such as 1 to 5 cm.

As described above, in some embodiments, the testing zone includes oneor more immobilized substances. In some embodiments, the immobilizedsubstances bind to specific regions of target material of agents orbiomarkers associated with the health condition(s) of interest). In someembodiments, the specific region(s) are the same as the region(s) thatthe non-immobilized (i.e. capable of migrating downstream) substance inthe reaction zone binds to. In some embodiments, the specific region(s)are different from the region(s) that the non-immobilized (i.e. capableof migrating downstream) substance(s) in the reaction zone bind to.

In some embodiments, the testing zone can include two or more testingsubstances, examples of which are described above. In some embodiments,the two or more testing substances are immobilized. In some embodiments,the testing zone includes two or more immobilized testing substanceswhen the reaction zone includes two or more non-immobilizedcorresponding reaction substances. In some embodiments, the two or morenon-immobilized reaction substances in the reaction region bind to thesame target substance of an agent or biomarker, and the two or moreimmobilized corresponding testing substances in the testing zone eachbinds to the same target substance of the agent or biomarker (can bindto the same specific region or a different region that thenon-immobilized reaction substance binds to). In some embodiments, thetwo or more non-immobilized reaction substances in the reaction zonebind to two or more different target materials of an agent or biomarker,and the two or more immobilized testing substances in the testing zoneeach bind to the same two or more target materials of the same agent orbiomarker (e.g., can bind to the same specific region or a differentregion that the non-immobilized reaction substance binds to). In someembodiments, the two or more non-immobilized reaction substances in thereaction zone bind to a specific region of target material of two ormore different agents or biomarkers, and the two or more immobilizedtesting substances in the testing zone each bind to the same targetmaterial of the two or more different agents or biomarkers.

In some embodiments, the two or more immobilized testing substances inthe testing zone are configured in a non-overlapping manner. In someembodiments, the two or more immobilized testing substances areseparated from each other in different regions of the testing zone withof distance of about 0.1 cm to 10 cm. In some embodiments, the two ormore immobilized testing substances are separated from each other indifferent regions of the testing zone with a distance of about at least0.01-5 cm.

In some embodiments, the two or more immobilized testing substances inthe testing zone are configured to be at least partially overlapping. Insome embodiments, the two or more immobilized substances completelyoverlap with each other.

In some embodiments, the affinity between the immobilized ornon-immobilized substance(s) and the target material to which thesubstance(s) specifically bind when they are specifically bound to eachother in a binding complex is characterized by a KD (dissociationconstant) of 10-5 M or less, 10-6 M or less, such as 10-7 M or less,including 10-8 M or less, e.g., 10-9 M or less, 10-10 M or less, 10-11 Mor less, 10-12 M or less, 10-13 M or less, 10-14 M or less, 10-15 M orless, including 10-16 M or less. “Affinity” refers to the strength ofbinding, increased binding affinity being correlated with a lower KD.

In some embodiments, the affinity between the immobilized testingsubstance in the testing zone and the target material of interest fromthe sample is about equal to or strong than the affinity between thenon-immobilized reaction substance in the reaction zone and the sametarget material. In some embodiments, the affinity between theimmobilized testing substance in the testing zone and the targetmaterial is at least about 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold thanthe affinity between the non-immobilized reaction substance in thereaction zone and the same target material.

In some embodiments, the affinity between the immobilized testingsubstance in the testing zone and the target material of interest fromthe sample is about equal to or weaker than the affinity between thenon-immobilized reaction substance in the reaction zone and the sametarget material. In some embodiments, the affinity between theimmobilized testing substance in the testing zone and the targetmaterial is at most about 90%, 80%, 70%, 60%, or 50% of the affinitybetween the non-immobilized reaction substance in the reaction zone andthe same target material.

In some embodiments (some of which are described above), the testingzone further includes a substance that binds to a biomarker ofpregnancy. In some embodiments, the biomarker(s) include one or more of:human chorionic gonadotropin (hCG), activin A, pregnancy-associatedplasma protein-A (PAPP-A), human placental lactogen (hPL), A disintegrinand Metalloprotease-12 (ADAM-12), pregnancy-specific beta glycoprotein 1(SP-1), placental mRNAs, progestrerone, Inhibin A, Vascular EndothelialGrowth Factor (VEGF), Placental-like growth factor (P1GF), LeukemicInhibitory Factor, Glycodelin, Mucin-1, Adrenomedullin, and otherbiomarkers.

In some embodiments (some of which are described above), the testingzone further includes a substance that binds to a biomarker offertility. In some embodiments, the biomarker(s) include one or more of:oestrone-3-glucuronide (E3G0, luteinizing hormone, follicle stimulatinghormone (FSH), estrogen, progesterone, testosterone,dehydroepiandrosterone (DHEA), cortisol, sex hormone binding globulin(SHBG), triiodothyronine (T3), Thyroxine (T4), thyroid stimulatinghormone (TSH), thyroid peroxidase antibodies (TPO antibodies), and otherbiomarkers.

1.3.9 System—Configuration of Testing Zone

In some embodiments (some of which are described above), the system alsoincludes a control zone. When present, the control zone is locateddownstream from the loading zone. In some embodiments, the control zoneis located upstream or downstream from, or overlaps with the reactionzone. In some embodiments, the control zone is located upstream ordownstream, or overlaps from the testing zone. In some embodiments, thecontrol zone is located downstream from both the reaction zone and thetesting zone.

In some embodiments, the control zone includes a control substance. Insome embodiments, the control substance is immobilized. In someembodiments, the control substance binds to any particle. In someembodiments, the substance binds to a mobile control binding agent (acontrol binding agent that is not immobilized). In some embodiments, themobile control binding agent is or includes the non-immobilized reactionsubstance in the reaction zone. In some embodiments, the mobile controlbinding agent is or includes an agent in the sample or a solution thesample is prepared in. In some embodiments, the control zone includestwo or more substances that bind to two or more mobile control bindingagents. In some embodiments, the two or more mobile control bindingagents are from different sources (e.g., one is from the sample or asolution the sample is prepared in, and another from the non-immobilizedsubstance originally in the reaction zone.)

1.3.10 System—Sensitivity and Specificity

In some embodiments, the system achieves a sensitivity of detecting thepresence of a specific agent or biomarker of at least about 50%, 55%,60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 90%, 92.5%, 95%, 96%, 97%, 98%, or99%. In some embodiments, the system detects two or more differentagents or biomarkers with a sensitivity for at least twoagents/biomarkers being both about or more than 50%, 55%, 60%, 65%, 70%,75%, 80%, 82.5%, 85%, 90%, 92.5%, 95%, 96%, 97%, 98%, or 99%. In someembodiments, the system detects three or more different agents orbiomarkers with a sensitivity for at least three agents/biomarkers beingboth about or more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%,90%, 92.5%, 95%, 96%, 97%, 98%, or 99%.

In some embodiments, the system achieves a specificity of detecting thepresence of a specific agent or biomarker of at least about 50%, 55%,60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 90%, 92.5%, 95%, 96%, 97%, 98%, or99%. In some embodiments, the system detects two or more differentagents or biomarkers with a specificity for at least twoagents/biomarkers being both about or more than 50%, 55%, 60%, 65%, 70%,75%, 80%, 82.5%, 85%, 90%, 92.5%, 95%, 96%, 97%, 98%, or 99%. In someembodiments, the system detects three or more different agents orbiomarkers with specificity for at least three agents/biomarkers beingboth about or more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%,90%, 92.5%, 95%, 96%, 97%, 98%, or 99%.

1.3.11 System—Detection System

In some embodiments, the system includes, is coupled to, or otherwisecommunicates with a detection system. In some embodiments, the detectionsystem includes an optical reader (e.g., an optical strip reader). Insome embodiments, the optical reader measures the intensity of colorsproduced at test and control lines. In some embodiments, the intensityof colors is recorded by an imaging software (e.g., an application on acomputer, such as a mobile app). In some embodiments, the intensity ofcolors are recorded by a camera and then processed by an imagingsoftware. In some embodiments, the optical system comprises a source oflight. In some embodiments, the source of light comprises amonochromatic light. In some embodiments, the optical system is anautomated system. In some embodiments, the optical system is a manualsystem.

In some embodiments, the detection system includes a fluorescence reader(e.g., a fluorescence strip reader). In some embodiments, thefluorescence reader measures the fluorescence intensity of test andcontrol lines.

In some embodiments, the detection system includes a photoelectricsensor. In some embodiments, the photoelectric sensor measuresphotoelectrons produced as a result of the colloidal gold being exposedto a light source.

In some embodiments, the detection system includes a magnetic reader(e.g., a magnetic strip reader). In some embodiments, the detectionsystem comprises an electrochemical detector.

In some embodiments, the system does not include an external detectionsystem. In some embodiments, the systems described herein produce asignal that can be assessed by the eye (e.g., with visual observation).

1.4 System—Component Variations

FIG. 4 depicts an embodiment of kit components configured to adjustsample extraction and processing parameters. As shown in FIG. 4, theembodiment of the extraction container 420 includes a tapered end 425for containing an extraction buffer. Such a configuration reduces samplevolume required and increases sample concentration within the extractionbuffer. The tapered end 425 of the extraction container 420 isconfigured to be complementary to the recessed surface 430 of thesampling kit. Similarly, the signal output device 440 includes a loadingzone 445 with a tapered end 447 configured to fit within the tapered end425 of the extraction container 420 and displace fluid within theextraction container 420, in order to facilitate transmission of theextracted target material from the sample to the testing zone 460 of thesignal output device 440.

2. Method

FIG. 5 depicts a flowchart of a method for assessing health of asubject, in accordance with one or more embodiments. The method 500 canbe implemented by one or more embodiments of the system(s) describedabove. As such, as shown in FIG. 5, once a sample is taken from asubject, the extraction container of a sampling kit can generate a firstsample phase 510 including a target material associated with the healthcondition, upon receiving a sample acquired directly from a subject intothe extraction container containing an extraction buffer. The samplingkit and signal output device then generates a second sample phase 520upon receiving a signal output device into the extraction container andflowing the first sample phase through a loading zone of the signaloutput device. The sampling kit and signal output device then generatesa third sample phase 530 upon flowing the second sample phase through areaction zone fluidly coupled to the loading zone and comprising a firstreaction substance conjugated to a first label, where the first reactionsubstance preferentially couples to the target material. The samplingkit and signal output device then generates a fourth sample phase 540upon flowing the third sample phase through a testing zone comprising afirst testing substance retained at the testing zone, where the firsttesting substance preferentially couples to the target material. Thesampling kit and signal output device then generates a fifth samplephase 550 upon flowing the fourth sample phase through a control zonecomprising a control substance immobilized at the control zone, wherethe control substance does not preferentially couple with the targetmaterial. Finally, the sampling kit and signal output device provide anoptically detected signal 560 characterizing status of the healthcondition from the testing zone and the control zone.

The method 500 is configured to operate with embodiments of theextraction containers, extraction buffers, loading zones, reactionzones, testing zones, control zones, substances, and labels describedabove. The method 500 is configured for detection of one or more healthconditions, including sexual health conditions described above.

FIG. 6 depicts a schematic of a method for providing and processing asample, in accordance with one or more embodiments. As shown in FIG. 6,an entity (e.g., a subject, an entity associated with the subject) opens601 packaging of a sampling kit of the system, which containsembodiments 602 of an extraction container, sample collecting tool,signal output device, and retention surface, as described above. Thecollection tool is operated upon 603 and receives 604 a sample from thesubject. The sample collecting tool with the sample is then transmitted605 into the extraction container to interact with an extraction buffer.Then, the signal output device is received 606 into the extractioncontainer, in order to transmit target material through the signaloutput device (e.g., as in steps 520-560 described above). In a relatedembodiment, as described in relation to FIGS. 7C and 7D below, thesample collecting tool can be integrated with the signal output device,such that the user can provide a sample to the sample collecting tool(e.g., by swabbing a collection site of the user's body), and thentransmit 605 the sample collection tool, which is coupled to the signaloutput device, into the extraction container.

Non-limiting examples of a sample can include vaginal fluid, vaginaltissue, vaginal washing, vaginal swab, vaginal discharge, cervical swab,cervical tissue urethral swab, urethral discharge, rectal swab, rectalmaterial, rectal washing, urine, blood, serum, plasma, saliva, tears,skin swab, semen, seminal fluid, sputum, bronchial fluid, bronchialwashing, peritoneal fluid, peritoneal washing, pleural fluid, pleuralwashing, cerebrospinal fluid, eye fluid and/or tissue, fluid and/ortissue from lung, liver, heart, brain, kidney, spleen or muscle and anycombination thereof. In some embodiments, the sample is a blood sample.In some embodiments, the sample is a urine sample. In some embodiments,the sample is a vaginal discharge or a penile discharge. In someembodiments, the sample is obtained from contacting an ulcer in genitalarea.

In some embodiments, the sample can be preabsorbed, e.g., to reduce orminimize cross-reactivity and/or background. As nonlimiting examples, insome embodiments, the biological sample can be preabsorbed with a lysateof bacteria expressing glutathione-S-transferase (GST) and/or a lysateof normal (e.g., non-pathogen infected mammalian cells). In someembodiments, absorption of the sample can be with a lysate ofpathogen-infected mammalian cells, to remove and/or block chlamydialantigen-specific antibodies from human samples, which can help confirmthe specificity of human antibody binding to the test analyte.

In some embodiments, the biological sample is obtained with a samplecollecting tool. In some embodiments, the sample collecting toolincludes a swab. In some embodiments, the swab is a vaginal swab orurethral swab. In some embodiments, the swab is an endocervical swab. Insome embodiments, the sample collecting tool comprises a fluidcollecting container. In some embodiments, the fluid collectingcontainer comprises a tube. In some embodiments, the tube is serum tubeor a plasma tube.

In some embodiments, the sample is or is recommended to be collected ata specific time or in a specific period of time. In some embodiments,the sample is or is recommended to be collected in the morning. In someembodiments, the sample is or is recommended to be collected within 1,2, 3, 4, 5, 6, or more hours before urinating. In some embodiments, thesample is or is recommended to be collected at noon. In someembodiments, the sample is or is recommended to be collected in theevening. In some embodiments, the sample is or is recommended to becollected before the shower. In some embodiments, the sample is or isrecommended to be collected before the individual having sex. In someembodiments, the sample is or is recommended to be collected after theindividual having sex. In some embodiments, the sample is or isrecommended to be collected within 1, 2, 3, 4, 5, 6 or more hours beforeor after the individual having sex. In some embodiments, the sample isor is recommended to be collected at least 4, 5, 6, 7, 8, 9, 10, 12 daysafter the individual ovulates.

In some embodiments, the biological sample is stable at room temperaturefor at least 1, 2, 4, 8, 12, 16, 20, 24 hours after obtained. In someembodiments, the sample is or is recommended to be tested within 1, 2,3, 4, 5, 6 hours after it is obtained. In some embodiments, the sampleis or is recommended to be tested shortly after it is obtained (forexample, within an hour).

FIG. 7A depicts a phase of usage of system components, in accordancewith the methods shown in FIGS. 5 and 6. As shown in FIG. 7A, a specificexample of the signal output device is received 706 a into an extractioncontainer in a manner analogous to that of step 606 described above, inorder to transmit target material through the signal output device(e.g., as in steps 520-560 described above). In the example of FIG. 7A,the packaging of the sampling kit provides a retention surface (similarto that of recessed surface 130 described above) to perform theexperiment in a resource limiting space.

FIG. 7B depicts another phase of usage of system components, inaccordance with the method shown in FIGS. 5 and 6. As shown in FIG. 7B,the specific example of the signal output device provides 760 a anoutput signal indicative of statuses of one or more health conditions ina manner analogous to that of Step 560 above. In a specific example ofStep 760 a, a result can be read from the signal output within 5-10minutes of providing a sample.

FIG. 7C depicts a phase of usage of an alternative embodiment of systemcomponents, in accordance with the methods shown in FIGS. 5 and 6. Asshown in FIG. 7C, a specific example of the signal output device isreceived 706 b into an extraction container in a manner analogous tothat of step 606 described above, in order to transmit target materialthrough the signal output device (e.g., as in steps 520-560 describedabove). In the example of FIG. 7C, the packaging of the sampling kitprovides a retention surface (similar to that of recessed surface 130described above) to perform the experiment in a resource limiting space.Furthermore, in the example of FIG. 7C, the embodiment of the signaloutput device includes a sample collecting tool (e.g., swab) 702 bintegrated with a distal region of the signal output device configuredto be inserted into extraction container. As such, the signal outputdevice can include an integrated sample collecting tool described inrelation to FIG. 6 above, where, during use, the user can provide asample with the sample collecting tool end of the signal output device,and transfer the sample collecting tool end of the signal output deviceinto the extraction container for sample processing with the extractionbuffer, as described above.

FIG. 7D depicts another phase of usage of an alternative embodiment ofsystem components, in accordance with the method shown in FIGS. 5 and 6.As shown in FIG. 7B, the specific example of the signal output deviceprovides 760 b an output signal indicative of statuses of one or morehealth conditions in a manner analogous to that of Step 560 above. In aspecific example of Step 760 b, a result can be read from the signaloutput within 5-10 minutes of providing a sample.

3. Conclusion

The foregoing description of the embodiments has been presented for thepurpose of illustration; it is not intended to be exhaustive or to limitthe patent rights to the precise forms disclosed. Persons skilled in therelevant art can appreciate that many modifications and variations arepossible in light of the above disclosure.

Any of the steps, operations, or processes described herein may beperformed or implemented with one or more hardware or software modules,alone or in combination with other devices.

Embodiments may also relate to an apparatus for performing theoperations herein. This apparatus may be specially constructed for therequired purposes, and/or it may comprise a general-purpose computingdevice selectively activated or reconfigured by a computer programstored in the computer. Such a computer program may be stored in anon-transitory, tangible computer readable storage medium, or any typeof media suitable for storing electronic instructions, which may becoupled to a computer system bus. Furthermore, any computing systemsreferred to in the specification may include a single processor or maybe architectures employing multiple processor designs for increasedcomputing capability.

Finally, the language used in the specification has been principallyselected for readability and instructional purposes, and it may not havebeen selected to delineate or circumscribe the patent rights. It istherefore intended that the scope of the patent rights be limited not bythis detailed description, but rather by any claims that issue on anapplication based hereon. Accordingly, the disclosure of the embodimentsis intended to be illustrative, but not limiting, of the scope of thepatent rights, one implementation of which is set forth in the followingclaims.

What is claimed is:
 1. A system for detection regarding a healthcondition, the system comprising: a sampling kit comprising: anextraction container containing an extraction buffer for extracting atarget material associated with the health condition, wherein theextraction buffer comprises phosphate buffered saline, Tris-bufferedsaline, HEPES buffered saline, and an extraction substance comprisingone or more of: 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate, a protein extraction reagent,octylthioglucoside, sodium hydroxide, Triton X-100, and octyl glucoside;a recessed surface of a housing of the sampling kit, the recessedsurface capable of retaining the extraction container in a retainedorientation; and a signal output device, wherein the signal outputdevice comprises: a loading zone insertable into the extractioncontainer in the retained orientation, a reaction zone connected to theloading zone and comprising a first reaction substance conjugated to afirst label, wherein the first reaction substance is capable ofpreferentially coupling to a first target of the target material, atesting zone connected to the reaction zone and comprising a firsttesting substance retained at a first region of the testing zone,wherein the first testing substance is capable of preferentiallycoupling to the first target of the target material; and a control zonecomprising a control substance retained at the control zone, wherein thecontrol substance is not capable of preferentially coupling to thetarget material.
 2. The system of claim 1, wherein the health conditionis an infection associated with Chlamydia trachomatis.
 3. The system ofclaim 2, wherein the first reaction substance and the first testingsubstance each comprise at least one of a set of antibodies and aptamerslisted in TABLE
 1. 4. The system of claim 1, wherein the healthcondition is an infection associated with Neisseria gonorrhoeae.
 5. Thesystem of claim 4, wherein the first reaction substance and the firsttesting substance each comprise at least one of a set of antibodies andaptamers listed in TABLE
 2. 6. The system of claim 1, wherein the healthcondition is an infection associated with Trichomonas vaginalis.
 7. Thesystem of claim 6, wherein the first reaction substance and the firsttesting substance each comprise at least one of a set of antibodies andaptamers listed in TABLE
 3. 8. The system of claim 1, wherein the healthcondition is associated with at least one of a sexually-transmittedinfection, a fertility status, and a pregnancy status.
 9. The system ofclaim 1, wherein the sampling kit comprises a process mode, wherein inthe process mode, the extraction container is retained at the recessedsurface, the loading zone is inserted into the extraction container, anda sample generated upon extraction of an agent by the extraction bufferflows against gravity through the loading zone, the reaction zone, thetesting zone, and the control zone.
 10. A system for detection regardinga health condition, the system comprising: a loading zone; a reactionzone connected to the loading zone and comprising: a first reactionsubstance conjugated to a first label, wherein the first reactionsubstance is capable of preferentially coupling to a first target oftarget material associated with the health condition, and a secondreaction substance conjugated to a second label, wherein the secondreaction substance is capable of preferentially coupling to a secondtarget of the target material; a testing zone connected to the reactionzone and comprising: a first testing substance retained at a firstregion of the testing zone, wherein the first testing substance iscapable of preferentially coupling to the first target of the targetmaterial, and a second testing substance retained at a second region ofthe testing zone, wherein the second testing substance is capable ofpreferentially coupling to the second target of the target material; anda control zone comprising a control substance retained at the controlzone, wherein the control substance is not capable of preferentiallycoupling to the target material.
 11. The system of claim 10, wherein thehealth condition is sexual health condition associated with at least oneof a Chlamydia trachomatis infection, a Neisseria gonorrhoeae infection,a Trichomonas vaginalis infection, a Treponema pallidum infection, aGardnerella vaginitis infection, human immunodeficiency virus, humanpapillomavirus infection, Hepatitis B, herpes simplex virus, a fertilitystatus, and a pregnancy status.
 12. The system of claim 11, wherein thefirst and the second reaction substances and the first and the secondtesting substances each comprise at least one of a set of antibodies andaptamers listed in TABLES 1, 2, and
 3. 13. The system of claim 10,wherein the first target comprises material from a first biomarker of afirst sexual health condition, and wherein the second target comprisesmaterial from a second biomarker of the first sexual health condition.14. The system of claim 11, further comprising an extraction containerconfigured to receive the loading zone, the extraction containercontaining an extraction buffer comprising phosphate buffered saline,Tris-buffered saline, HEPES buffered saline, and an extraction substancecomprising one or more of: 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate, a protein extraction reagent,octylthioglucoside, sodium hydroxide, Triton X-100, and octyl glucoside.15. The system of claim 14, wherein the extraction buffer is capable ofextracting target material associated with a set of health conditionsassociated with a set of infectious agents.
 16. The system of claim 15,wherein the first target comprises material from a first infectiousagent associated with a first sexual health condition of the set ofhealth conditions, and wherein the second target comprises material froma second infectious agent associated with a second sexual healthcondition different from the first sexual health condition.
 17. Thesystem of claim 16, wherein the first region of the testing zone isdefined in a first pathway and wherein the second region of the testingzone is fluidly isolated from the first pathway.
 18. A method fordetecting status of a health condition, the method comprising:generating a first sample phase comprising a target material associatedwith the health condition, upon receiving a sample acquired directlyfrom a subject into an extraction container containing an extractionbuffer; generating a second sample phase upon receiving a signal outputdevice into the extraction container and flowing the first sample phasethrough a loading zone of the signal output device; generating a thirdsample phase upon flowing the second sample phase through a reactionzone fluidly coupled to the loading zone and comprising a first reactionsubstance conjugated to a first label, wherein the first reactionsubstance preferentially couples to the target material; generating afourth sample phase upon flowing the third sample phase through atesting zone comprising a first testing substance retained at thetesting zone, wherein the first testing substance preferentially couplesto the target material; generating a fifth sample phase upon flowing thefourth sample phase through a control zone comprising a controlsubstance immobilized at the control zone, wherein the control substancedoes not preferentially couple with the target material; and providingan optically detected signal characterizing status of the healthcondition from the testing zone and the control zone.
 19. The method ofclaim 18, wherein the health condition is sexual health conditionassociated with at least one of a Chlamydia trachomatis infection, aNeisseria gonorrhoeae infection, a Trichomonas vaginalis infection, aTreponema pallidum infection, a Gardnerella vaginitis infection, humanimmunodeficiency virus, human papillomavirus infection, Hepatitis B,herpes simplex virus, a fertility status, and a pregnancy status. 20.The method of claim 19, wherein the extraction buffer comprisesphosphate buffered saline, Tris-buffered saline, HEPES buffered saline,and an extraction substance comprising one or more of:3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate, a proteinextraction reagent, octylthioglucoside, sodium hydroxide, Triton X-100,and octyl glucoside.
 21. The method of claim 20, wherein the firstreaction substance and the first testing substance each comprise atleast one of a set of antibodies and aptamers listed in TABLES 1, 2, and3.